Tirzepatide

the active ingredient in Mounjaro® and Zepbound®.

A dual GIP/GLP-1 receptor agonist, prescribed based on individual evaluation and treatment history.

How it works

Activates both GIP and GLP-1 receptors, a dual mechanism distinct from single-target GLP-1 therapies.

Who it's typically considered for

Adults evaluated as candidates for GLP-1-class therapy, particularly where semaglutide response has been limited.

Common side effects

• — Nausea
• — Diarrhea
• — Vomiting
• — Injection-site reactions

Who should not take this

• — Pregnancy or breastfeeding
• — Personal or family history of medullary thyroid carcinoma or MEN2
• — Known hypersensitivity to tirzepatide